For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Biomarkers for Early Detection of Alzheimer PathologyClark C.M.a, d-f · Davatzikos C.b · Borthakur A.b · Newberg A.b · Leight S.c, g · Lee V.M.-Y.c, f, g · Trojanowski J.Q.c-g
Departments of aNeurology, bRadiology and cPathology and Laboratory Medicine, dCenter of Excellence for Research on Neurodegenerative Diseases, eAlzheimer Disease Center, fInstitute on Aging, and gCenter for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pa., USA Corresponding Author
Chris M. Clark, MD
Penn – Ralston Center, University of Pennsylvania
3615 Chestnut Street
Philadelphia, PA 19104 (USA)
Tel. +1 215 662 7810, Fax +1 215 662 7812, E-Mail firstname.lastname@example.org
The increasing prevalence of Alzheimer’s disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T1ρ to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer’s disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.
© 2008 S. Karger AG, Basel